Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

119
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
119
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

656
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
656
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

136
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
136
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

315
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
315
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.0K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

182
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
182
这页已由机器翻译。其他页面可能仍然显示为英文。View in English
  1. 首页
  2. 研究领域
  3. 关于原住民的研究
  4. 太平洋人民的健康和福祉
  5. 太平洋人民的健康文化决定因素
  6. 维里西瓜特与安慰剂对心力衰竭和保存排泄部分患者的生活质量的影响:vitality- Hfpef随机临床试验

维里西瓜特与安慰剂对心力衰竭和保存排泄部分患者的生活质量的影响:VITALITY- HFpEF随机临床试验

Paul W Armstrong1, Carolyn S P Lam2, Kevin J Anstrom3

  • 1Division of Cardiology, Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada.

JAMA
|October 20, 2020

相关实验视频

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.6K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.8K
Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.6K

在PubMed 上查看摘要

概括
此摘要是机器生成的。

在心力衰竭患者中,Vericiguat没有改善心力衰竭患者的身体限制. 这项研究评估了

科学领域:

  • 心脏病学
  • 药理学
  • 临床试验

背景情况:

  • 心脏衰竭与保存的喷射分数 (HFpEF) 显著增加死亡风险,住院,并降低生活质量.
  • 患有HFpEF的患者会出现严重的身体限制,影响日常功能.

研究的目的:

  • 评估通过口服可溶性甘氨酸环酶刺激剂的 vericiguat 在改善HFpEF患者的物理限制得分 (PLS) 的有效性.
  • 为了评估 vericiguat对堪萨斯市心肌病问卷 (KCCQ) 物理限制得分 (PLS) 的影响.

主要方法:

  • 一个2b期,随机,双盲,安慰剂控制的多中心试验,涉及789名慢性HFpEF患者.
  • 患者接受了达特西瓜特 (每天10毫克或15毫克) 或安慰剂24周.
  • 主要结局是KCCQ PLS从基线到24周的变化;次要结局是6分钟步行距离的变化.

主要成果:

  • 与安慰剂相比,Vericiguat治疗 (每天10mg或15mg) 并没有导致KCCQ PLS的统计学上显著改善.
  • 在KCCQ PLS中最小平方值的平均变化为5. 5 mg (15 mg组),6. 4 mg (10 mg组) 和6. 9 mg (安慰剂组).
  • 给予者和安慰剂组之间的6分钟步行距离没有显著差异. 症状性低血压发生的频率略高于给予者组.

相关实验视频

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.6K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.8K
Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.6K

结论:

  • 在患有HFpEF且近期失补偿的患者中,通过KCCQ PLS测量,24周的 vericiguat治疗没有改善身体限制.
  • 这些发现表明, vericiguat可能不是改善HFpEF群体身体功能的有效治疗方法.
  • 可能需要进一步的研究来探索用于功能改善HFpEF的替代治疗策略.